# Seer, Inc.: overview SEER · Nasdaq · CIK 1726445 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/seer.md) · [Financials](/companies/seer/financials.md) · [Filings](/companies/seer/filings.md) · [Insiders](/companies/seer/insiders.md) Latest reported revenue: [$3.1m](/filings/0001193125-26-344858.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-344858). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.0](/filings/0001193125-25-269727.md) | [4.0 d](/filings/0001193125-26-085481.md) | [4.2](/filings/0001193125-26-221724.md) | [4.1](/filings/0001193125-26-344858.md) | [4.1](/filings/0001193125-25-269727.md) | [4.2 d](/filings/0001193125-26-085481.md) | [2.8](/filings/0001193125-26-221724.md) | [3.1](/filings/0001193125-26-344858.md) | | Gross margin | % | [48.1%](/filings/0001193125-25-269727.md) | [50.6% d](/filings/0001193125-26-085481.md) | [49.0%](/filings/0001193125-26-221724.md) | [52.1%](/filings/0001193125-26-344858.md) | [51.2%](/filings/0001193125-25-269727.md) | [52.0% d](/filings/0001193125-26-085481.md) | [35.2%](/filings/0001193125-26-221724.md) | [48.5%](/filings/0001193125-26-344858.md) | | Operating margin | % | [(603.3%)](/filings/0001193125-25-269727.md) | [(587.2%) d](/filings/0001193125-26-085481.md) | [(493.0%)](/filings/0001193125-26-221724.md) | [(506.8%)](/filings/0001193125-26-344858.md) | [(469.4%)](/filings/0001193125-25-269727.md) | [(413.8%) d](/filings/0001193125-26-085481.md) | [(617.8%)](/filings/0001193125-26-221724.md) | [(542.9%)](/filings/0001193125-26-344858.md) | | Net margin | % | [(529.0%)](/filings/0001193125-25-269727.md) | [(543.6%) d](/filings/0001193125-26-085481.md) | [(474.4%)](/filings/0001193125-26-344858.md) | [(479.5%)](/filings/0001193125-26-344858.md) | [(442.5%)](/filings/0001193125-25-269727.md) | [(380.7%) d](/filings/0001193125-26-085481.md) | [(602.8%)](/filings/0001193125-26-344858.md) | [(544.8%)](/filings/0001193125-26-344858.md) | | Diluted EPS | $ per share | [(0.35)](/filings/0000950170-24-122343.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(16.3) d](/filings/0001193125-25-269727.md) | [(12.0) d](/filings/0001193125-26-085481.md) | [(12.1)](/filings/0001193125-26-221724.md) | [(15.2) d](/filings/0001193125-26-344858.md) | [(7.8) d](/filings/0001193125-25-269727.md) | [(11.1) d](/filings/0001193125-26-085481.md) | [(15.7)](/filings/0001193125-26-221724.md) | [(9.6) d](/filings/0001193125-26-344858.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [6.6](/filings/0001628280-23-006564.md) | [15.5](/filings/0000950170-24-024967.md) | [16.7](/filings/0000950170-25-030878.md) | [14.2](/filings/0001193125-26-085481.md) | [16.6](/filings/0001193125-26-085481.md) | | Gross margin | % | [51.6%](/filings/0001628280-23-006564.md) | [45.8%](/filings/0000950170-24-024967.md) | [51.1%](/filings/0000950170-25-030878.md) | [49.8%](/filings/0001193125-26-085481.md) | [51.1%](/filings/0001193125-26-085481.md) | | Operating margin | % | [(1080.1%)](/filings/0001628280-23-006564.md) | [(627.6%)](/filings/0000950170-24-024967.md) | [(621.0%)](/filings/0000950170-25-030878.md) | [(706.4%)](/filings/0001193125-26-085481.md) | [(470.5%)](/filings/0001193125-26-085481.md) | | Net margin | % | [(1075.5%)](/filings/0001628280-23-006564.md) | [(600.1%)](/filings/0000950170-24-024967.md) | [(517.8%)](/filings/0000950170-25-030878.md) | [(611.1%)](/filings/0001193125-26-085481.md) | [(444.0%)](/filings/0001193125-26-085481.md) | | Diluted EPS | $ per share | [(1.17)](/filings/0001628280-23-006564.md) | [(1.49)](/filings/0000950170-24-024967.md) | [(1.35)](/filings/0000950170-24-024967.md) | not reported | not reported | | Free cash flow | $m | [(53.3)](/filings/0001628280-23-006564.md) | [(71.0)](/filings/0000950170-24-024967.md) | [(66.4)](/filings/0000950170-25-030878.md) | [(49.7)](/filings/0001193125-26-085481.md) | [(46.2)](/filings/0001193125-26-085481.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/seer/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [SOFTBANK GROUP CORP.](/funds/1065521.md) | 2026-06-30 | $8.5m | 5,135,383 | | Unchanged | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $4.1m | 2,458,673 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.0m | 1,831,058 | | Reduced −127,938 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.4m | 1,428,405 | | Reduced −393,199 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $1.6m | 985,500 | | Added +8,812 | | [NANO CAP NEW MILLENNIUM GROWTH FUND L P](/funds/1277890.md) | 2026-06-30 | $1.4m | 825,000 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $862.1k | 519,310 | | New +519,310 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $817.2k | 492,298 | | Reduced −19,300 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $764.5k | 460,430 | | Added +37,453 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $762.7k | 459,443 | | Unchanged | ## Recent filings [All 396 filings](/companies/seer/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-18 | 16:06 ET | [8-K](/filings/0001193125-26-395523.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-395523 | | 2026-08-11 | 16:41 ET | [10-Q](/filings/0001193125-26-344858.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344858 | | 2026-08-11 | 16:23 ET | [8-K](/filings/0001193125-26-344748.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344748 | | 2026-07-31 | 16:35 ET | [8-K](/filings/0001193125-26-328733.md) | 5.07 Shareholder vote results | 0001193125-26-328733 | | 2026-07-31 | 07:47 ET | [8-K](/filings/0001193125-26-326858.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-326858 | | 2026-07-20 | 16:08 ET | [8-K](/filings/0001193125-26-308919.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-308919 | | 2026-07-02 | 17:28 ET | [8-K](/filings/0001193125-26-294994.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-294994 | | 2026-05-22 | 08:11 ET | [8-K](/filings/0001193125-26-235517.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-235517 | | 2026-05-13 | 16:28 ET | [10-Q](/filings/0001193125-26-221724.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221724 | | 2026-05-13 | 16:19 ET | [8-K](/filings/0001193125-26-221696.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221696 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-085481.md), filed Mar 2, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/fddc4965-f44d-4c39-84fb-3ef1d4e903ee) ## About the filer - CIK: 1726445 - Tickers: SEER - Exchange: Nasdaq - SIC code: 3826 Laboratory Analytical Instruments - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:42 ET. No prices; not investment advice.